```
FILE 'USPATFULL' ENTERED AT 12:59:16 ON 20 AUG 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l2 or hydroxyapatite or (hydroxy apatite) or l3 or (calcium phosphate)
or acp
L5        81733 L2 OR HYDROXYAPATITE OR (HYDROXY APATITE) OR L3 OR (CALCIUM
                PHOSPHATE) OR ACP

=> s l2 or hydroxyapatite or (hydroxy apatite) or l3 or (calcium phosphate)
or cap
<------User Break------>
u
=> d l4
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y



L4   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2002 ACS
RN   33069-62-4  REGISTRY
CN   Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,

(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-
     2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-
     tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl
     ester, (.alpha.R,.beta.S)- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid
     deriv.
CN   Benzenepropanoic acid, .beta.-(benzoylamino)-.alpha.-hydroxy-,
     6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-
     dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
     cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-

[2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(.alpha.R*,.beta.S*),11.alpha.
     ,12.alpha.,12a.alpha.,12b.alpha.]]-
CN   Tax-11-en-9-one,
5.beta.,20-epoxy-1,2.alpha.,4,7.beta.,10.beta.,13.alpha.-
     hexahydroxy-, 4,10-diacetate 2-benzoate 13-ester with
(2R,3S)-N-benzoyl-3-
     phenylisoserine (8CI)
OTHER NAMES:
CN   ABI 007
CN   BMS 181339-01
CN   NSC 125973
CN   Paclitaxel
CN   Plaxicel
CN   Taxol
CN   Taxol A
CN   Yewtaxan
FS   STEREOSEARCH
MF   C47 H51 N O14
CI   COM
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
       BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
       CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*,
       DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, HSDB*, IFICDB,
       IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PHAR, PHARMASEARCH,
       PIRA, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL,
VETU
         (*File contains numerically searchable property data)
```

Absolute stereochemistry. Rotation (-).



6294 REFERENCES IN FILE CA (1967 TO DATE)
338 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6328 REFERENCES IN FILE CAPLUS (1967 TO DATE)

COPYRIGHT 2002 ACS
AN 2002:408483 CAPLUS
DN 137:10969
TI Chemotherapeutic composition using nanocrystalline calcium phosphate paste
IN Lee, Dosuk D.; Aiolova, Maria
PA Etex Corporation, USA
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002041844	A2	20020530	WO 2001-US51419	20011019

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-693120 A2 20001020

L9 ANSWER 2 OF 3 USPATFULL
AN 2002:24062 USPATFULL
TI Apatite-coated solid composition
IN Saito, Kazuhiro, Suita, JAPAN
Hoshino, Tetsuo, Osaka, JAPAN
PA Takeda Chemical Industries, Ltd., Osaka, JAPAN (non-U.S. corporation)
PI US 6344209 B1 20020205
WO 9847485 19981029
AI US 1999-403414 19991020 (9)
WO 1998-JP1870 19980423
19991020 PCT 371 date
PRAI JP 1997-106918 19970424
DT Utility
FS GRANTED
LN.CNT 1519
INCL INCLM: 424/426.000
INCLS: 424/457.000; 424/462.000; 424/486.000; 424/489.000; 424/490.000; 424/463.000; 514/772.300; 514/963.000
NCL NCLM: 424/426.000
NCLS: 424/457.000; 424/462.000; 424/463.000; 424/486.000; 424/489.000; 424/490.000; 514/772.300; 514/963.000
IC [7]
ICM: A61F002-00
ICS: A61K009-52; A61K009-58; A61K009-14; A61K047-30
EXF 424/426; 424/501; 424/457; 424/462; 424/463; 424/486; 424/489; 514/963; 514/772.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 3 USPATFULL
AN 2001:188689 USPATFULL
TI Taxol-like protein (TALP) and process for preparing the same
IN Hwang, Byung-Doo, Taejon, Korea, Republic of
Lim, Kyu, Taejon, Korea, Republic of
Kwak, Sang-Tae, Chungcheongbuk-do, Korea, Republic of

Kweon, Gi-Ryang, Daegu, Korea, Republic of
Yoon, Wan-Hee, Taejon, Korea, Republic of
PA Byung-Doo Hwang (non-U.S. corporation)
PI US 2001034322 A1 20011025
AI US 2001-799409 A1 20010305 (9)
RLI Continuation of Ser. No. US 1999-269146, filed on 12 Mar 1999, PENDING
A
371 of International Ser. No. WO 1996-KR158, filed on 12 Sep 1996,
UNKNOWN
DT Utility
FS APPLICATION
LN.CNT 665
INCL INCLM: 514/002.000
INCLS: 435/184.000
NCL NCLM: 514/002.000
NCLS: 435/184.000
IC [7]
ICM: C12N009-99
ICS: A61K038-57
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

L16 ANSWER 1 OF 232 USPATFULL

ACCESSION NUMBER:	2002:209101 USPATFULL
TITLE:	**Hydroxyapatite**-targeting poly (ethylene glycol) and related polymers
INVENTOR(S):	Roberts, Michael James, Madison, AL, United States Kozlowski, Antoni, Huntsville, AL, United States
PATENT ASSIGNEE(S):	Shearwater Corporation, Huntsville, AL, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6436386	B1	20020820	
APPLICATION INFO.:	US 2000-712536		20001114	(9)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	GRANTED			
PRIMARY EXAMINER:	Page, Thurman K.			
ASSISTANT EXAMINER:	Fubara, Blessing			
LEGAL REPRESENTATIVE:	Alston & Bird LLP			
NUMBER OF CLAIMS:	80			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)			
LINE COUNT:	1412			

OF 232 USPATFULL

ACCESSION NUMBER: 2002:157058 USPATFULL

TITLE: 21784, a novel human calcium channel family member and uses thereof

INVENTOR(S): Curtis, Rory A.J., Southborough, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002081657	A1	20020627
APPLICATION INFO.:	US 2001-875423	A1	20010605 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209257P	20000605 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804

NUMBER OF CLAIMS: 31

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 4 Drawing Page(s)

LINE COUNT: 5663

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 21784 nucleic acid molecules, which encode novel calcium channel

L19 ANSWER 47 OF 132 USPATFULL
ACCESSION NUMBER: 2002:136533 USPATFULL
TITLE: Method for delivering bioactive agents using cochleates
INVENTOR(S): Unger, Evan C., Tucson, AZ, United States
PATENT ASSIGNEE(S): Imarx Therapeutics, Inc., Tucson, AZ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6403056	B1	20020611
APPLICATION INFO.:	US 2000-540448		20000331 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1997-925353, filed on 8 Sep 1997, now patented, Pat. No. US 6120751
Continuation-in-part of Ser. No. US 1997-823791, filed on 21 Mar 1997, now patented, Pat. No. US 6143276
Continuation-in-part of Ser. No. US 1997-851780, filed on 6 May 1997, now patented, Pat. No. US 6090800
Continuation-in-part of Ser. No. US 1997-877826, filed on 18 Jun 1997 Continuation-in-part of Ser. No. US 1997-887215, filed on 2 Jul 1997, now patented, Pat. No. US 6028066
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Hartley, Michael G.
LEGAL REPRESENTATIVE: Woodcock Washburn LLP
NUMBER OF CLAIMS: 63
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 6445
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to charged lipids, compositions comprising charged lipids, and the use of these compositions in **drug delivery**, targeted **drug delivery**, therapeutic imaging and diagnostic imaging, as well as their use as contrast agents.

L19 ANSWER 130 OF 132 USPATFULL
ACCESSION NUMBER: 96:111166 USPATFULL
TITLE: Therapeutic **drug delivery** systems
INVENTOR(S): Unger, Evan C., Tucson, AZ, United States
Fritz, Thomas A., Tucson, AZ, United States
Matsunaga, Terry, Tucson, AZ, United States
Ramaswami, VaradaRajan, Tucson, AZ, United States
Yellowhair, David, Tucson, AZ, United States
Wu, Guanli, Tucson, AZ, United States
PATENT ASSIGNEE(S): ImaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5580575		19961203
APPLICATION INFO.:	US 1993-76250		19930611 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1991-716899, filed on 18 Jun 1991, now abandoned And a continuation-in-part of Ser. No. US 1991-717084, filed on 18 Jun 1991, now patented, Pat. No. US 5228446 which is a continuation-in-part of Ser. No. US 1990-569828, filed on 20 Aug 1990, now patented, Pat. No. US 5088499 which is a continuation-in-part of Ser. No. US 1989-455707, filed on 22 Dec 1989, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kishore, Gollamudi S.
LEGAL REPRESENTATIVE: Woodcock Washburn Kurtz Mackiewicz & Norris
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT: 2932
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Therapeutic **drug delivery** systems comprising

L19 ANSWER 128 OF 132 USPATFULL
ACCESSION NUMBER: 97:122866 USPATFULL
TITLE: Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
INVENTOR(S): Cha, Younsik, Salt Lake City, UT, United States
Choi, Young Kweon, Salt Lake City, UT, United States
Bae, You Han, Kwangju, Korea, Republic of
PATENT ASSIGNEE(S): Macromed, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5702717		19971230	
APPLICATION INFO.:	US 1995-548185		19951025	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dean, Ralph H.
LEGAL REPRESENTATIVE: Thorpe, North & Western, L.L.P.
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
LINE COUNT: 1194
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A system and method for the parenteral delivery of a drug in a biodegradable polymeric matrix to a warm blooded animal as a liquid with the resultant formation of a **gel** depot for the controlled release of the drug. The system comprises an **injectable** biodegradable block copolymeric **drug delivery** liquid having reverse thermal gelation properties. The delivery liquid is an aqueous solution having dissolved or dispersed therein an effective amount of a drug intimately contained in a biodegradable block copolymer matrix. The copolymer has a reverse gelation temperature below the body temperature of the animal to which it is administered and is made up of (i) a hydrophobic A polymer block comprising a member selected from the group consisting of poly(.alpha.-hydroxy acids) and poly(ethylen

L19 ANSWER 99 OF 132 USPATFULL
ACCESSION NUMBER: 2001:188729 USPATFULL
TITLE: WATER SOLUBLE **PACLITAXEL** DERIVATIVES
INVENTOR(S): LI, CHUN, MISSOURI CITY, TX, United States
WALLACE, SIDNEY, HOUSTON, TX, United States
YU, DONG-FANG, HOUSTON, TX, United States
YANG, DAVID J., SUGAR LAND, TX, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001034363	A1	20011025
APPLICATION INFO.:	US 1998-50662	A1	19980330 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-815104, filed on 11 Mar 1997, GRANTED, Pat. No. US 5977163

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-13184P	19960312 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: RONALD J. KAMIS, FOLEY & LARDNER, 3000 K STREET N.W., SUITE 500, WASHINGTON, DC, 20007-5109
NUMBER OF CLAIMS: 51
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 2480
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are water soluble compositions of **paclitaxel** and docetaxel formed by conjugating the **paclitaxel** or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis.

Other embodiments include the coating of implantable stents for prevention of restenosis.

132 USPATFULL

ACCESSION NUMBER: 2002:54341 USPATFULL

TITLE: Delivery of therapeutic biologicals from implantable tissue matrices

INVENTOR(S): MacLaughlin, David T., Saugus, MA, UNITED STATES
Vacanti, Joseph P., Winchester, MA, UNITED STATES
Donahoe, Patricia K., Boston, MA, UNITED STATES
Masiakos, Peter T., Boston, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002031500	A1	20020314
APPLICATION INFO.:	US 2001-770339	A1	20010126 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-178842P	20000127 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Patrea L. Pabst, Arnall Golden & Gregory, LLP, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA, 30309-3450
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Normal cells, such as fibroblasts or other tissue or organ cell types, are genetically engineered to express biologically active, therapeutic agents, such as proteins that are normally produced in small amounts, for example, MIS, or other members of the TGF-beta family Herceptin.TM., interferons, andanti-angiogenic factors. These cells are seeded into a matrix for implantation into the patient to be treated. Cells may also be engineered to include a lethal gene, so that implanted cells can be destroyed once treatment is completed. Cells can be implanted in a variety of different matrices. In a preferred embodiment, these matrices are implantable and biodegradable over a period of time equal to or less than the expected period of treatment, when cells engraft to form a